Dosing + Administration Guide for CIDP

Give your patients a treatment option with VYVGART Hytrulo, a once-weekly subcutaneous injection for adults with CIDP.^{1*}



*Do not dilute VYVGART Hytrulo. Allow for appropriate storage, preparation, and setup time before use.¹

CIDP=chronic inflammatory demyelinating polyneuropathy.

INDICATION

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope.

Please see additional Important Safety Information throughout and full <u>Prescribing Information</u>. VYVGART[®] Hytrulo

efgartigimod alfa and hyaluronidase-qvfc)

Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

Recommended dosage for CIDP

One injection, once weekly¹

Recommended dosage

 1,008 mg/11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase)¹

- Once-weekly injections¹
- Administered subcutaneously over approximately 30-90 seconds¹
 - · Refers to actual injection time¹
 - Healthcare professionals should monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration¹

Scheduling for CIDP

VYVGART Hytrulo is dosed **weekly** for adults with **CIDP**. Plan to accommodate the weekly treatment schedule of patients with **CIDP**.¹

If a scheduled injection is missed

VYVGART Hytrulo may be administered **up to 3 days** after the scheduled time point. Thereafter, resume the original dosing schedule.¹

Immunization

Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART Hytrulo. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART Hytrulo are unknown. Because VYVGART Hytrulo causes a reduction in IgG levels, vaccination with live vaccines is **not recommended** during treatment with VYVGART Hytrulo.¹

CIDP=chronic inflammatory demyelinating polyneuropathy; IgG=immunoglobulin G.

IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS Infection

VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 in patients with gMG were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcabvs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.



Not actual size.

IMPORTANT SAFETY INFORMATION (cont'd) Immunization

Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VVVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.

Please see additional Important Safety Information throughout and full <u>Prescribing Information</u>.

Preparing VYVGART Hytrulo

VYVGART Hytrulo is for subcutaneous use only and is administered with a winged infusion set 25G, 12-inch tubing, made of polyvinyl chloride (PVC), and a maximum priming volume of 0.4 mL^{-1}

~	•				· · ·		
Suppl	ies n	eedeo	a tor	adm	inis	trat	ior

· Alcohol swabs	· Adhesive bandage
· One 10-mL syringe	One FDA-cleared sharps container
• One winged infusion set (25G x 12 inches)	· One 18G transfer needle (2-inch length)
· One sterile gauze	

It is important to use an aseptic technique when preparing and administering VYVGART Hytrulo.¹

Store VYVGART Hytrulo vials refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light until time of use. Do not freeze. Do not shake.¹

VYVGART Hytrulo does not contain preservatives and must be administered immediately after preparation.¹

IMPORTANT SAFETY INFORMATION (cont'd)

Hypersensitivity Reactions

In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation in gMG. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Healthcare professionals should monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.

Setting up the injection


STEP 1

Take the vial out of the refrigerator at least 15 minutes before injecting and allow it to reach room temperature. Do not use external heat sources.¹



STEP 2

Visually inspect the solution to ensure it is yellowish, clear to opalescent. Do not use if opaque particles or other foreign particles are present.¹



STEP 3

Withdraw the entire contents of VYVGART Hytrulo from the vial using a polypropylene syringe and an 18G stainless steel transfer needle.¹



STEP 4

Remove large air bubbles if present.1



IMPORTANT SAFETY INFORMATION (cont'd) Infusion-Related Reactions

Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.

Please see additional Important Safety Information throughout and full <u>Prescribing Information</u>.

Administering VYVGART Hytrulo

Preparing the injection

STEP 1

Remove the transfer needle from the syringe and connect the syringe to the winged infusion set.¹

STEP 2

Fill the tubing of the winged infusion set by gently pressing the syringe plunger until the plunger is at 5.6 mL. There should be solution at the end of the winged infusion set needle.¹

Administering the injection

STEP 1

Choose an injection site on the abdomen at least 2-3 inches from the navel. Do not inject on areas where the skin is red, bruised, tender, or hard, or into areas where there are moles or scars. Rotate injection sites for subsequent administrations.¹

STEP 2

Inject VYVGART Hytrulo subcutaneously into an area of pinched skin at an angle of about 45 degrees over 30-90 seconds.¹

Localized injection site reactions may occur after VYVGART Hytrulo is administered.¹

IMPORTANT SAFETY INFORMATION (cont'd) ADVERSE REACTIONS

Patients with gMG: In Study 1, the most common (≥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the most common (≥10%) adverse reactions in VYVGART HYTRULO-treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 2 and its open-label extension in patients with gMG, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.

After the injection



Once administration is complete, discard any solution remaining in the vial, the syringe, and the winged infusion set.¹



STEP 2

Healthcare professionals should monitor for clinical signs and symptoms of **hypersensitivity reactions** for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed, or the patient should seek medical attention.¹



VYVGART Hytrulo is to be administered by a **healthcare professional** only. VYVGART Hytrulo is for **subcutaneous** use only and administered with a winged infusion set. Do not administer intravenously.¹

IMPORTANT SAFETY INFORMATION (cont'd) ADVERSE REACTIONS (cont'd)

Patients with CIDP: In Study 3 stage B, the overall safety profile observed in patients with CIDP treated with VYVGART HYTRULO was consistent with the known safety profile of VYVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously. In Study 3, injection site reactions occurred in 15% of patients treated with VYVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.

Please see additional Important Safety Information throughout and full <u>Prescribing Information</u>.



Administering VYVGART Hytrulo (cont'd)

Potential injection site reactions


In the ADHERE trial, injection site reactions occurred in 15% of patients treated with VYVGART Hytrulo compared to 6% of patients who received placebo.¹

- Most common injection site reactions were injection site bruising and injection site erythema¹
- · All injection site reactions were mild to moderate in severity¹
- Most injection site reactions occurred during the first 3 months of treatment¹

Hypersensitivity reactions

In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART Hytrulo or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART Hytrulo. Hypersensitivity reactions were mild or moderate and occurred within 1 hour to 3 weeks of administration.¹

Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation.¹



IMPORTANT SAFETY INFORMATION (cont'd)

Lactation

There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal condition.

Please see additional Important Safety Information throughout and full <u>Prescribing Information</u>.

IMPORTANT SAFETY INFORMATION (cont'd) USE IN SPECIFIC POPULATIONS Pregnancy

As VYVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART HYTRULO in utero.

INDICATION AND IMPORTANT SAFETY INFORMATION INDICATION

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope.

WARNINGS AND PRECAUTIONS

Infection

VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 in patients with gMG were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebotreated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.

Immunization

Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.

Hypersensitivity Reactions

In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VVVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VVVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation in gMG. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Healthcare professionals should monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.

Infusion-Related Reactions

Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and premedications.

ADVERSE REACTIONS

Patients with gMG: In Study I, the most common (≥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the most common (≥10%) adverse reactions in VYVGART HYTRULO-treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VVVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 2 and its open-label extension in patients with gMG, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.

Patients with CIDP: In Study 3 stage B, the overall safety profile observed in patients with CIDP treated with VVVGART HYTRULO was consistent with the known safety profile of VVVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously. In Study 3, injection site reactions occurred in 15% of patients treated with VVVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.

USE IN SPECIFIC POPULATIONS Pregnancy

As VVVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VVVGART HYTRULO in utero.

Lactation

There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VVVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VVVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal condition.

Please see the full Prescribing Information.

You may report side effects to the US Food and Drug Administration by visiting <u>http://www.fda.gov/medwatch</u> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).

(efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection For more information on dosing and administration for VYVGART Hytrulo, visit VYVGARTHCP.com/hytrulo-CIDP/dosing

INDICATION

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS


VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope.

Please see additional Important Safety Information throughout and full <u>Prescribing Information</u>.

Reference: 1. VYVGART Hytrulo. Prescribing information. argenx US Inc; 2024.



For US audiences only. VVVGART is a registered trademark of argenx. VVVGART Hytrulo is a trademark of argenx. © 2024 argenx US-VVV_HYT-24-00517 VI 11/2024. All Rights Reserved.



(efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial